Artielle ImmunoTherapeutics

Artielle ImmunoTherapeutics is a clinical-stage, venture-backed biotech company developing first-in-class biologic drugs using its proprietary recombinant T cell receptor ligand platform. Its lead candidate, RTL1000, completed a Phase I safety study in multiple sclerosis patients and showed an acceptable safety profile with some adverse events at higher doses. The company’s pipeline includes additional preclinical programs targeting neuroinflammatory and autoimmune diseases such as optic neuritis, stroke, uveitis, RA, AMD, celiac disease, and methamphetamine addiction. The RTL technology aims to modulate immune responses by targeting autoreactive T cells and related inflammatory pathways.